Pasithea Therapeutics Corp. · NASDAQ:KTTA
Pasithea Therapeutics — Investor Presentation (September 2026)
20 slides from Pasithea Therapeutics's investor presentation, September 2026
Slide 1: Corporate Overview
Corporate Overview Sept 2026
Slide 2: Company disclaimer
Company disclaimer Certain statements set forth in this presentation by Pasithea Therapeutics Corp’s (the “Company”) contain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect the Company’s plans, beliefs, expectations and
Slide 3: Pipeline focused on developing PAS-004 for multiple indications
Pipeline focused on developing PAS-004 for multiple indications PAS-004 is being developed for the long-term treatment of chronic diseases including the neurocutaneous manifestations of NF1 Study Indication Preclinical Phase 1 Phase 2 Phase 3 Comments Updated interim RAS, RAF, NF1 data to be PAS-004
Slide 4: Senior leadership
Senior leadership • Endowed Chair in the Neurology Dept. at Stanford University. Member of the National Academy of Dr. Lawrence Steinman Sciences. - Executive Chairman & Co-Founder • Founded and served on board of successful biotech companies, including Neurocrine Biosciences Inc. (Founder and Board
Slide 5: PAS-004: Designed to reduce RAS pathway signaling
PAS-004: Designed to reduce RAS pathway signaling • The RAS-PAPK pathway is a key regulator • PAS-004 was designed to unite the of cellular proliferation and survival. favorable properties of previous MEK • Activating mutations in RAS or RAF have inhibitors been described in many cancers where GAP •
Slide 6: NF1-PN and NF1-CN: Two distinct opportunities within one rare disease
NF1-PN and NF1-CN: Two distinct opportunities within one rare disease NF1 is caused by a germline mutation in the NF1 tumor suppressor gene and affects ~1 in 3,000 people worldwide Plexiform Neurofibromas (PN) Cutaneous Neurofibromas (CN) Tumor response is assessed via volumetric MRI imaging (REiNS
Slide 7: NF1 is a large market opportunity
NF1 is a large market opportunity NF1 Worldwide MEK inhibitor sales for NF1-PN1 ~1 in 3,000 births 2 $M, worldwide ~115,000 people with NF1 in the U.S. 30–50% develop PN · >95% develop CN 71 NF1-PN Multi billion TAM 630 531 ~50,000 total patients in the U.S. ~16,000 diagnosed, non-resectable (MEKi e
Slide 8: NF1-PN: A concentrated, high-need patient opportunity
NF1-PN: A concentrated, high-need patient opportunity PN segmentation is driven by symptom burden and surgical operability, concentrating unmet need in a smaller, more severe population – PN affects an estimated ~30-50% of NF1 patients (~50K total U.S. prevalence); ~70% are diagnosed, ~50,000 yieldi
Slide 9: NF1-CN: a large, universal patient opportunity
NF1-CN: a large, universal patient opportunity Cutaneous neurofibromas (CN) develop in virtually all NF1 patients, creating a large population that spans a wide range of disease severity – CN is the most prevalent NF1 manifestation — ~95-100% of NF1 patients develop ≥1 CN over their ~115,000 lifetim
Slide 10: Untreated CNs Keep Growing — and Patients Are Motivated to Treat Them
Untreated CNs Keep Growing — and Patients Are Motivated to Treat Them 8-year prospective study of 22 adults with NF1¹ alongside a 548-patient survey² — CN burden compounds over time, and willingness to treat is high CN VOLUME — FOLD INCREASE OVER 96 MONTHS Willingness to Try New Treatments 2.6× 1.64
Slide 11: Opportunities to improve on current NF1-PN treatment
Opportunities to improve on current NF1-PN treatment Adult-population data from the pivotal KOMET (selumetinib) and ReNeu (mirdametinib) trials reveal a clear tolerability and dosing-burden gap A D UL T T R EA T M E NT -R E L AT E D A D VE R S E E V EN T B UR D E N — R E A D A CR OS S BY AGE N T Dis
Slide 12: PAS-004-103: Ongoing Phase in Lead Indication of NF1
PAS-004-103: Ongoing Phase 1 in Lead Indication of NF1 Adult participants with NF1 with symptomatic and inoperable, incompletely resected, or recurrent PNs Part A: 3+3 Dose Escalation Study Design Part B Dose Expansion Two Part A dose levels will be selected and randomized to determine RP2D R Recomm
Slide 13: PAS-004-102: Ongoing open-label dose escalation Phase I clinical trial in cancer
PAS-004-102: Ongoing open-label dose escalation Phase I clinical trial in cancer Patients with MAPK pathway driven solid tumors with a documented RAS, NF1, or RAF mutations or patients who have failed BRAF/MEK inhibition Food Effect Cohorts TRIAL OBJECTIVES Primary Secondary Food Effect • To evaluat
Slide 14: PAS-004 demonstrates favorable human PK Properties in cancer study
PAS-004 demonstrates favorable human PK Properties in cancer study PAS-004 dosing QD PAS-004 dosing QD Mirdametinib dosing BID Selumetinib dosing BID Mirdametinib dosing BID Selumetinib dosing BID Steady State Parameter PAS-004 Mirdametinib1 Selumetinib 2 Dosing regimen 37 mg QD 4 mg BID 25 mg/m2 BI
Slide 15: Signal of activity in BRAF mutated tumors
Signal of activity in BRAF mutated tumors (n=7 evaluable patients) ✓ Initial Disease Control Rate (DCR) of 71.4% in BRAF-mutated tumors: 5 of 7 patients achieved stable disease ✓ 2 Patients now with over 1 year on treatment without evidence of disease progression TUMOR TYPE MUTATION Target Lesion Pe
Slide 16: PAS-004 demonstrates a tolerable safety profile
PAS-004 demonstrates a tolerable safety profile 1 Cohort 1 Cohort 2 Cohort 3 Cohort 4A Cohort 4B Cohort 5 Cohort 6 Cohort 7 Total number of patients 2mg 4mg 8mg 15mg 4mg tablet 22 mg 30 mg 37 mg N=3 N=3 N=3 N=3 N=4 N=4 N=5 N=3 Selected, Percentage Related AEs of patients (All Grade 1 and 2) with eve
Slide 17: Mirdametinib PK and AE profile from its Phase 1 trial in advanced cancer
Mirdametinib PK and AE profile from its Phase 1 trial in advanced cancer PK profile with large Cmax to Cmin variability1 Adverse events observed even at the lowest dose level, including rash and diarrhea1 1. LoRusso PM et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kin
Slide 18: Intellectual property
Intellectual property Composition of Matter patent issued • US patent 9034861, Exclusivity protection until Sept 2032 with extension estimated to be March 2037 • Additional 6-month exclusivity for pediatric application • Patent issued in multiple geographies New Composition of Matter patents filed i
Slide 19: Engineered for the treatment sweet spot in NF1 and other chronic conditions
Engineered for the treatment sweet spot in NF1 and other chronic conditions Robust Better Efficacy Tolerability PAS-004 Sweet Spot Convenient Dosing
Slide 20: Financial overview
Financial overview Founded / IPO 2020 / 2021 Stock Price (1) $0.574 Nasdaq KTTA Common Shares Outstanding (1) 33.41 M Market Cap $19.2 M Primary Shares Outstanding (2) 88.24 M Primary Market Cap (2) $50.7 M Fully Diluted Shares Outstanding (2,3) 107.68 M 52 Week Low – High (1) $0.292 / $1.47 Cash Ba
Pasithea Therapeutics — Investor Presentation (September 2026) on 6ix